|
|
|
| Research progress of CC chemokine receptor 9/CC chemokine ligand 25 in related diseases |
| XU Hanzhe HUANG Yan |
| Department of Cardiology, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, China |
|
|
|
|
Abstract Chemokine is a structure-related protein with a relatively small molecular weight, which can target cells to chemotaxis and promote inflammatory response. CC chemokine receptor 9 (CCR9) and CC chemokine ligand 25 (CCL25) are involved in the regulating the occurrence and development of various diseases. Early research have confirmed various physiological functions including migration and maturation of inflammatory cells. Subsequent studies have confirmed that CCR9/CCL25 plays an important role in the pathological processes of various inflammatory and non inflammatory diseases such as inflammatory bowel disease, rheumatoid arthritis, cardiovascular disease, tumors, and other diseases. Therefore, this review provides an overview of the latest progress of CCR9/CCL25 in various diseases, which is beneficial for in-depth research on CCR9/CCL25. CCR9/CCL25 is expected to become a potential target for drug therapy.
|
|
|
|
|
|
[1] Wu X，Sun M，Yang Z，et al. The roles of CCR9/CCL25 in inflammation and inflammation-associated diseases [J]. Front Cell Dev Biol，2021，9：686548.
[2] Hong Z，Wei Z，Xie T，et al. Targeting chemokines for acute lymphoblastic leukemia therapy [J]. J Hematol Oncol，2021， 14（1）：48.
[3] Wang C，Liu Z，Xu Z，et al. The role of chemokine receptor 9/ chemokine ligand 25 signaling：from immune cells to cancer cells [J]. Oncol Lett，2018，16（2）：2071-2077.
[4] Lynch KD，Chapman RW，Keshav S，et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases [J]. Clin Gastroenterol Hepatol，2020，18（1）：179.e6-187.e6.
[5] Koda Y，Nakamoto N，Chu PS，et al. CCR9 axis inhibition enhances hepatic migration of plasmacytoid DCs and protects against liver injury [J]. JCI Insight，2022，7（17）：e159910.
[6] Umar S，Palasiewicz K，Van Raemdonck K，et al. CCL25 and CCR9 is a unique pathway that potentiates pannus formation by remodeling RA macrophages into mature osteoclasts [J]. Eur J Immunol，2021，51（4）：903-914.
[7] Yu H，Mei Y，Dong Y，et al. CCR9-CCL25 mediated plasmacytoid dendritic cell homing and contributed the immunosuppressive microenvironment in gastric cancer [J]. Transl Oncol，2023，33：101682.
[8] Xu B，Deng C，Wu X，et al. CCR9 and CCL25：a review of their roles in tumor promotion [J]. J Cell Physiol，2020，235（12）：9121-9132.
[9] Osorio-Barrios F，Navarro G，Campos J，et al. The heteromeric complex formed by dopamine receptor D5 and CCR9 leads the Gut homing of CD4+ T cells upon inflammation [J]. Cell Mol Gastroenterol Hepatol，2021，12（2）：489-506.
[10] Trivedi PJ，Bruns T，Ward S，et al. Intestinal CCL25 expression is increased in colitis and correlates with inflammatory activity [J]. J Autoimmun，2016，68：98-104.
[11] Trivedi PJ，Adams DH. Chemokines and chemokine receptors as therapeutic targets in inflammatory bowel disease；pitfalls and promise [J]. J Crohns Colitis，2018，12（suppl 2）：S641-S652.
[12] Jia H，Sodhi CP，Yamaguchi Y，et al. Toll like receptor 4 mediated lymphocyte imbalance induces NEC-induced lung injury [J]. Shock，2019，52（2）：215-223.
[13] Ma F，Li S，Gao X，et al. Interleukin-6-mediated CCR9+ interleukin-17-producing regulatory T cells polarization increases the severity of necrotizing enterocolitis [J]. EBio- Medicine，2019，44：71-85.
[14] Li F，Hao H，Gao X，et al. Potential for CCR9+IL-17+regulatory T cell as a predictor of early necrotizing enterocolitis [J]. Neonatology，2022，119（3）：320-326.
[15] Graham JJ，Mukherjee S，Yuksel M，et al. Aberrant hepatic trafficking of gut-derived T cells is not specific to primary sclerosing cholangitis [J]. Hepatology，2022，75（3）：518- 530.
[16] Goode E，Panousis N，Fachal L，et al. Transcriptome and colocalisation analysis of CCR9+gut-homing T cells and other immune cells identifies important genes and biological pathways potentiating primary sclerosing cholangitis risk [J]. J Hepatol，2020，73：S42-S43.
[17] Hinrichs AC，Kruize AA，Leavis HL，et al. In patients with primary Sj?觟gren’s syndrome innate-like MAIT cells display upregulated IL-7R，IFN-γ，and IL-21 expression and have increased proportions of CCR9 and CXCR5-expressing cells [J]. Front Immunol，2022，13：1017157.
[18] Schmutz C，Cartwright A，Williams H，et al. Monocytes/ma- crophages express chemokine receptor CCR9 in rheumatoid arthritis and CCL25 stimulates their differentiation [J]. Art- hritis Res Ther，2010，12（4）：R161.
[19] Huang Y，Ding HS，Song T，et al. Abrogation of CC chemokine receptor 9 ameliorates ventricular electrical remodeling in mice after myocardial infarction [J]. Front Cardiovasc Med，2021，8：716219.
[20] Huang Y，Wang D，Wang X，et al. Abrogation of CC chemok- ine receptor 9 ameliorates ventricular remodeling in mice after myocardial infarction [J]. Sci Rep，2016，6：32660.
[21] Xu Z，Mei F，Liu H，et al. C-C motif chemokine receptor 9 exacerbates pressure overload-induced cardiac hypertrophy and dysfunction [J]. J Am Heart Assoc，2016，5（5）：e003342.
[22] Kong H，Yu W，Chen Z，et al. Correction to：CCR9 initiates epithelial-mesenchymal transition by activating Wnt/β- catenin pathways to promote osteosarcoma metastasis [J]. Cancer Cell Int，2022，22（1）：152.
[23] Chai SL，Wen ZH，Zhang RX，et al. CCL25/CCR9 interaction promotes the malignant behavior of salivary adenoid cystic carcinoma via the PI3K/AKT signaling pathway [J]. Peer J，2022，10：e13844.
[24] Lu L，Du H，Huang H，et al. CCR9 promotes migration and invasion of lung adenocarcinoma cancer stem cells [J]. Int J Med Sci，2020，17（7）：912-920.
[25] Korbecki J，Grochans S，Gutowska I，et al. CC Chemokines in a tumor：a review of pro-cancer and anti-cancer properties of receptors CCR5，CCR6，CCR7，CCR8，CCR9，and CCR10 ligands [J]. Int J Mol Sci，2020，21（20）：7619.
[26] Somovilla-Crespo B，Martin Monzon MT，Vela M，et al. 92R monoclonal antibody inhibits human CCR9+ leukemia cells growth in NSG mice xenografts [J]. Front Immunol，2018，9：77.
[27] Li J，Muhammad J，Xie T，et al. LINC00853 restrains T cell acute lymphoblastic leukemia invasion and infiltration by regulating CCR9/CCL25 [J]. Mol Immunol，2021，140：267- 275.
[28] Herbst RS，Morgensztern D，Boshoff C. The biology and management of non-small cell lung cancer [J]. Nature，2018， 553（7689）：446-454.
[29] Niu Y，Tang D，Fan L，et al. CCL25 promotes the migration and invasion of non-small cell lung cancer cells by regulating VEGF and MMPs in a CCR9-dependent manner [J]. Exp Ther Med，2020，19（6）：3571-3580.
[30] Chen H，Cong X，Wu C，et al. Intratumoral delivery of CCL25 enhances immunotherapy against triple-negative breast cancer by recruiting CCR9+ T cells [J]. Sci Adv，2020，6（5）： eaax4690. |
|
|
|
